APA

Fyfe D., Raynaud F., Langley R. E., Newell D. R., Halbert G., Gardner C., Clayton K., Woll P. J., Judson I. & Carmichael J. (20020308). A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. : Cancer chemotherapy and pharmacology.

Chicago

Fyfe D, Raynaud F, Langley R E, Newell D R, Halbert G, Gardner C, Clayton K, Woll P J, Judson I and Carmichael J. 20020308. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. : Cancer chemotherapy and pharmacology.

Harvard

Fyfe D., Raynaud F., Langley R. E., Newell D. R., Halbert G., Gardner C., Clayton K., Woll P. J., Judson I. and Carmichael J. (20020308). A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. : Cancer chemotherapy and pharmacology.

MLA

Fyfe D, Raynaud F, Langley R E, Newell D R, Halbert G, Gardner C, Clayton K, Woll P J, Judson I and Carmichael J. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. : Cancer chemotherapy and pharmacology. 20020308.